Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9013541 | 0.89 | ABCG2 (0.54) | ESR2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL9013519 | 0.85 | KDM4E (0.55) | SMN1; SMN2TP53MAPK1MAPTMEN1 | |
| SCHEMBL338452 | 0.83 | CLK4 (0.64) | ESR2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL11247361 | 0.82 | NPC1 (0.64) | ESR2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL15805573 | 0.82 | ESR2 (0.72) | ESR2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2876553 | 0.81 | CLK4 (0.61) | ESR2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL15896952 | 0.81 | CLK4 (0.61) | ESR2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL12888412 | 0.79 | ADORA3 (0.54) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL6516972 | 0.78 | NPC1 (0.66) | ESR2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL13658285 | 0.78 | NPC1 (0.66) | ESR2NPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158787-B2 | Process for producing trichloropyrimidine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20100160630-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2128141-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-6372751-B1 | DRUGS WITH BENZENE AND PYRIMIDINE RINGS | BERLEX LABORATORIES, INC. | 2002-04-16 | — | — | US | disclosed |
| EP-1135131-A4 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LAB (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1135131-A1 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6127376-A | A BLOOD FACTOR XA ENZYME INHIBITOR TREATING A HUMAN HAVING A DISEASE-STATE CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000033844-A1 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LATORATORIES, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| CN-1233393-A | Use of selective herbicidal compositions and method of treatment | NITROKEMIA 2000 RT (HU) | 1999-11-03 | — | — | CN | disclosed |
| EP-0055693-B1 | USE OF PHENYL PYRIMIDINES AS PROTECTING AGENTS FOR CULTURE PLANTS AGAINST PHYTOTOXIC DAMAGE CAUSED BY HERBICIDES | CIBA-GEIGY AG (CH) | 1988-01-20 | — | — | EP | disclosed |
| US-4674229-A | SEEDS COATED WITH PLANT SAFENING AGENT | CIBA-GEIGY CORPORATION (US) | 1987-06-23 | — | — | US | disclosed |
| EP-0136976-A2 | Use of phenyl pyrimidines as plant regulators | CIBA-GEIGY AG (CH) | 1985-04-10 | — | — | EP | disclosed |
| US-4493726-A | PLANT SAFENING AGENT | CIBA GEIGY CORPORATION (US) | 1985-01-15 | — | — | US | disclosed |
| EP-0055693-A1 | Use of phenyl pyrimidines as protecting agents for culture plants against phytotoxic damage caused by herbicides | CIBA-GEIGY AG (CH) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160630-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | DPYD, TYMP, TST | ESR2 2601/4885NPC1 4790/4885RAB9A 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.